Clinical trials · New York
Breast Cancer Stage III clinical trials in New York
We’re tracking 69 recruiting breast cancer stage iii studies with a site in New York — including Phase 1, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07459673RecruitingPhase 2
HER2-positive breast cancer trial using ctDNA to guide treatment
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
Uniondale, New YorkAges 18 years+ - NCT07310420RecruitingPhase 1
Evaluating ovarian suppression with ZOLADEX in premenopausal breast cancer
This trial tests a medication (ZOLADEX) to suppress ovarian function in premenopausal women with hormone receptor-positive breast cancer, either early-stage or advanced. The goal is to see how well it works and how safe it is.
Amsterdam, New YorkAges 18–55 - NCT07225309Recruiting
Meaning-Centered Therapy for Mexican Adults with Advanced Cancer
This study tests a therapy program called Meaning-Centered Therapy designed to help adults in Mexico with advanced cancer find meaning and improve their well-being. It involves sessions delivered by trained providers at the National Cancer Institute in Mexico (INCan).
New York, New YorkAges 18 years+ - NCT07109817RecruitingPhase 2
Desloratadine to prevent nerve damage from taxane chemo in breast cancer
This trial tests if the allergy medicine desloratadine can prevent nerve damage (numbness, tingling, pain) caused by taxane chemotherapy in people with early-stage breast cancer. Taking desloratadine daily during chemo may help protect your nerves.
The Bronx, New YorkAges 18 years+ - NCT07102381RecruitingPhase 2
Zanidatamab plus chemo before surgery for HER2+ breast cancer
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Camillus, New YorkAges 18 years+ - NCT07042581RecruitingPhase 4
Revaree Plus for vaginal dryness in breast cancer survivors
This trial tests a vaginal insert called Revaree Plus to see if it helps breast cancer survivors who have vaginal dryness or pain from hormone therapy. It may be a good option if you are on an aromatase inhibitor or tamoxifen and have discomfort.
Uniondale, New YorkAges 18 years+ - NCT07017829RecruitingPhase 2
Combination therapy for STK11-mutant lung cancer
This trial tests a new drug (GT103) combined with the approved immunotherapy drug pembrolizumab for people with advanced lung cancer that has a specific genetic change (STK11). The goal is to see if adding GT103 helps control the cancer better than pembrolizumab alone.
Buffalo, New YorkAges 18 years+ - NCT06958328RecruitingPhase 3
Higher dose radiation for locally advanced pancreatic cancer
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
Brooklyn, New YorkAges 18 years+ - NCT06748222RecruitingPhase 3
Online mindfulness program for breast cancer survivors
This trial tests a 6-week online mindfulness program to help breast cancer survivors manage mild to moderate depression. You may qualify if you finished active treatment within the last 5 years and can use a digital device.
New York, New YorkAges 18–50 - NCT06733350RecruitingPhase 4
Testosterone therapy for low testosterone in men with low-risk prostate cancer
This study tests whether testosterone replacement therapy can safely improve low testosterone levels in men with low-risk prostate cancer who are not getting immediate treatment. It aims to help men feel better without worsening their cancer.
Buffalo, New YorkAges 18 years+ - NCT06721065Recruiting
Study of interpretation services for breast cancer patients
This study tests different ways of providing language interpretation during breast cancer or gastrointestinal cancer visits at MSK. It aims to improve communication for patients who prefer Spanish or Mandarin and have limited English proficiency.
Rockville Centre, New YorkAges 18 years+ - NCT06532279RecruitingPhase 2
Testing BMX-001 with chemoradiation for head and neck cancer
This trial tests whether adding BMX-001 (a drug that may protect healthy tissues) to standard chemoradiation can reduce side effects and improve outcomes for people with head and neck cancer. It's a randomized study, so you would have a 50/50 chance of getting BMX-001 or a placebo.
The Bronx, New YorkAges 18 years+ - NCT06434064RecruitingPhase 2
Tamoxifen and chemotherapy for triple negative breast cancer
This trial tests a combination of tamoxifen (a hormonal therapy) and pegylated liposomal doxorubicin (a type of chemotherapy) for people with triple negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination can help people whose cancer has not responded to at least two prior treatments.
Buffalo, New YorkAges 18 years+ - NCT06275126Recruiting
Choosing the Best Surgery for Young Women with Breast Cancer
This study looks at how to make the best surgical choices for young women with breast cancer. It compares different surgery options to help guide treatment decisions.
New York, New YorkAges 18–44 - NCT00823654Recruiting
Blood tests during treatment to track ovarian egg supply
This study measures blood biomarkers to understand how breast cancer treatment affects a person’s future fertility (ovarian reserve). It may help patients learn more about egg supply changes after chemotherapy and hormone-related treatments.
New York, New YorkAges 18–44 - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Brooklyn, New YorkAges 18 years+ - NCT03694756Recruiting
Testing special MRI to see tiny breast cancer structures
This study is testing whether a special MRI scan can help show tiny features inside breast tumors (TMEM). It’s mainly a “feasibility” study, meaning the team is checking if the scan can be done safely and clearly in different types of operable breast cancer.
The Bronx, New YorkAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Rochester, New YorkAges 65 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Staten Island, New YorkAges 18 years+ - NCT05741164RecruitingPhase 2
Propranolol plus pembrolizumab for hard-to-treat breast cancer
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
Buffalo, New YorkAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Buffalo, New YorkAges Any age - NCT05570253RecruitingPhase 2
SDX-7320 plus eribulin for metastatic triple-negative breast cancer
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
Commack, New YorkAges 18 years+ - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
New York, New YorkAges 18 years+ - NCT05408845RecruitingPhase 2
Study drug vs standard care for HER2 salivary gland cancer
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
New York, New YorkAges 18 years+
Breast Cancer Stage III trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting breast cancer stage iii studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- Memorial Sloan Kettering Westchester · 8 studies
- Montefiore Medical Center · 8 studies
- Memorial Sloan Kettering Nassau · 7 studies
- Roswell Park Comprehensive Cancer Center · 7 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 6 studies
- Mount Sinai Health System · 5 studies
- NYU Langone Health · 5 studies
What taking part in a breast cancer stage iii study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Breast Cancer Stage III trials in other states
Common questions
- Are there breast cancer stage iii clinical trials in New York?
- Yes. We're currently tracking 69 recruiting breast cancer stage iii studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a breast cancer stage iii study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a breast cancer stage iii trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New breast cancer stage iii studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.